This company listing is no longer active
ENDP.Q Stock Overview
A specialty pharmaceutical company, develops, manufactures, markets, and sells various pharmaceutical products in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Endo Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0006 |
| 52 Week High | US$0.08 |
| 52 Week Low | US$0.000001 |
| Beta | 0.80 |
| 1 Month Change | 50.00% |
| 3 Month Change | 0% |
| 1 Year Change | -98.91% |
| 3 Year Change | -99.99% |
| 5 Year Change | -99.99% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Endo creditors looking at putting company up for sale through bankruptcy - Bloomberg
Aug 16Endo International sees 23% rise on 3x higher than normal volume
Aug 03Endo outperforms defying bankruptcy fears and generic entry
Jul 25Endo weighs bankruptcy filing without opioid settlement - WSJ
Jul 12Endo International cools off, giving back some of its 85% Tuesday gain
Jun 29Endo: Stick A Fork In It
May 10Endo: About As Bad As It Gets
Mar 07Endo: FDA Approves Generic Form Of Vasostrict Creating Headwind Into Next Year
Dec 16Endo: A Win In California But Equity Value Still A Question
Nov 02Endo International: Loses Vasostrict Trial
Aug 31Endo International: Hires Restructuring Advisor
Aug 20Endo International: All About Ongoing Litigation
Aug 07Endo: Appellate Court Denies Request To Postpone Damages Trial Might Be End O' The Road
Jul 15Endo International: Bankruptcy Seems Like The Only Practical Option
Jun 30Endo International wins FDA approval for Micafungin new formulation
Jun 17Endo International plc 2021 Q1 - Results - Earnings Call Presentation
May 07Radius Health partners with Endo unit for abaloparatide in Canada
Jan 05Shareholder Returns
| ENDP.Q | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -1.6% | -2.4% |
| 1Y | -98.9% | 7.8% | 23.3% |
Return vs Industry: ENDP.Q underperformed the US Pharmaceuticals industry which returned 12.5% over the past year.
Return vs Market: ENDP.Q underperformed the US Market which returned 22.8% over the past year.
Price Volatility
| ENDP.Q volatility | |
|---|---|
| ENDP.Q Average Weekly Movement | 207.3% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ENDP.Q's share price has been volatile over the past 3 months.
Volatility Over Time: ENDP.Q's weekly volatility has increased from 125% to 207% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 2,931 | Blaise Coleman | www.endo.com |
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. It operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The company offers branded pharmaceuticals, including XIAFLEX to treat adult patients with Dupuytren’s contracture and Peyronie’s disease; SUPPRELIN LA to treat central precocious puberty in children; AVEED to treat hypogonadism; NASCOBAL nasal spray to treat vitamin B12 deficiency; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET for pain management; TESTOPEL, an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; and EDEX to treat erectile dysfunction, as well as opioid products to treat pain associated with post-herpetic neuralgia.
Endo Inc. Fundamentals Summary
| ENDP.Q fundamental statistics | |
|---|---|
| Market cap | US$141.13k |
| Earnings (TTM) | -US$2.45b |
| Revenue (TTM) | US$2.01b |
0.0x
P/S Ratio0.0x
P/E RatioIs ENDP.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ENDP.Q income statement (TTM) | |
|---|---|
| Revenue | US$2.01b |
| Cost of Revenue | US$941.90m |
| Gross Profit | US$1.07b |
| Other Expenses | US$3.52b |
| Earnings | -US$2.45b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -10.41 |
| Gross Margin | 53.17% |
| Net Profit Margin | -121.69% |
| Debt/Equity Ratio | -123.5% |
How did ENDP.Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/05/02 13:16 |
| End of Day Share Price | 2024/05/02 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Endo Inc. is covered by 44 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Richard Silver | Barclays |
| Gary Nachman | BMO Capital Markets Equity Research |
| Sumant Satchidanand Kulkarni | BofA Global Research |